INSM INSMED Inc
Price (delayed)
$73.44
Market cap
$13.29B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.57
Enterprise value
$14.05B
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved
Highlights
INSM's revenue is up by 19% year-on-year and by 6% since the previous quarter
The company's gross profit rose by 16% YoY and by 4.9% QoQ
The equity has soared by 186% YoY but it is down by 41% from the previous quarter
The company's quick ratio rose by 37% YoY but it fell by 14% QoQ
INSMED's net income has decreased by 22% YoY and by 6% QoQ
The EPS has declined by 4.3% year-on-year
Key stats
What are the main financial stats of INSM
Market
Valuations
Earnings
Shares outstanding
181M
Market cap
$13.29B
Enterprise value
$14.05B
Price to earnings (P/E)
N/A
Price to book (P/B)
46.04
Price to sales (P/S)
33.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
38.62
Revenue
$363.71M
Gross profit
$277.97M
Operating income
-$878.25M
Net income
-$913.77M
EBIT
-$825.15M
EBITDA
-$810.55M
Free cash flow
-$705.81M
Per share
Balance sheet
Liquidity
EPS
-$5.57
EPS diluted
-$5.57
Free cash flow per share
-$4.3
Book value per share
$1.6
Revenue per share
$2.22
TBVPS
$11.16
Total assets
$2.03B
Total liabilities
$1.74B
Debt
$1.31B
Equity
$285.38M
Working capital
$1.32B
Debt to equity
4.59
Current ratio
5.45
Quick ratio
4.99
Net debt/EBITDA
-0.93
Margins
Efficiency
Dividend
EBITDA margin
-222.9%
Gross margin
76.4%
Net margin
-251.2%
Operating margin
-241.5%
Return on assets
-51.9%
Return on equity
-1,066.2%
Return on invested capital
-46.4%
Return on capital employed
-47.8%
Return on sales
-226.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
INSM stock price
How has the INSMED stock price performed over time
Intraday
2%
1 week
-4.09%
1 month
-9.94%
1 year
179.24%
YTD
6.37%
QTD
-3.74%
Financial performance
How have INSMED's revenue and profit performed over time
Revenue
$363.71M
Gross profit
$277.97M
Operating income
-$878.25M
Net income
-$913.77M
Gross margin
76.4%
Net margin
-251.2%
INSMED's operating income has decreased by 24% YoY and by 6% QoQ
INSMED's net income has decreased by 22% YoY and by 6% QoQ
INSM's revenue is up by 19% year-on-year and by 6% since the previous quarter
The company's gross profit rose by 16% YoY and by 4.9% QoQ
Growth
What is INSMED's growth rate over time
Valuation
What is INSMED stock price valuation
P/E
N/A
P/B
46.04
P/S
33.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
38.62
The EPS has declined by 4.3% year-on-year
The equity has soared by 186% YoY but it is down by 41% from the previous quarter
INSM's price to sales (P/S) is 84% higher than its 5-year quarterly average of 17.6 and 16% higher than its last 4 quarters average of 28.1
INSM's revenue is up by 19% year-on-year and by 6% since the previous quarter
Efficiency
How efficient is INSMED business performance
The ROIC has declined by 19% year-on-year
The company's return on assets rose by 4.6% QoQ and by 2.8% YoY
The ROS has declined by 4.1% year-on-year
Dividends
What is INSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for INSM.
Financial health
How did INSMED financials performed over time
INSM's total assets is 16% higher than its total liabilities
INSM's total assets has soared by 52% YoY
The company's quick ratio rose by 37% YoY but it fell by 14% QoQ
The equity has soared by 186% YoY but it is down by 41% from the previous quarter
The debt to equity has soared by 91% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.